

Our mission
We aim to improve outcomes and quality of life for patients with prostate, bladder or kidney cancer.
Goals
- To find early diagnostic indicators that can accurately identify patients with localized tumors, who are likely to benefit from curative treatment, while avoiding unnecessary biopsies or more agressive management.
- To develop and evaluate new diagnostic and treatment modalities with better efficacy and tolerability outcomes.
- To find pre- and on-treatment biomarkers to identify patients likely to respond to specific therapies.
- To optimize the risk-benefit ratio of available anti-cancer drugs through early identification of non-responders, pharmalogical interventions and dose individualization.
- To identify host-related risk factors to guide strategies for primary and tertiary prevention.